Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Nuclear Cardiology
Published in: Journal of Nuclear Cardiology 1/2019

01-02-2019 | Theme Article

State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis

Authors: Vasvi Singh, MD, Rodney Falk, MD, Marcelo F. Di Carli, MD, Marie Kijewski, PhD, Claudio Rapezzi, MD, Sharmila Dorbala, MD

Published in: Journal of Nuclear Cardiology | Issue 1/2019

Login to get access

Abstract

Cardiac amyloidosis, once considered untreatable, is now gaining well-deserved attention due to advances in imaging and the recent approval of targeted breakthrough therapies. In this paper, we discuss the role of radionuclide imaging in the evaluation and management of patients with the most common form of amyloidosis—cardiac transthyretin amyloidosis (ATTR). We provide a comprehensive summary of the literature interspersed with our institutional experience as appropriate, to deliver our perspective.
Appendix
Available only for authorised users
Literature
1.
Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Adams AV, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med 2018;379:11-21.
2.
Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med 2018;379:22-31.CrossRefPubMed
3.
4.
Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med 2015;372:21-9.CrossRefPubMedPubMedCentral
5.
Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.PubMed
6.
7.
Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Adv Ther 2015;32:920-8.CrossRefPubMedPubMedCentral
8.
Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation 2014;129:1840-9.CrossRefPubMed
9.
Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol 2017;70:466-77.CrossRefPubMed
10.
Quarta CC, Gonzalez-Lopez E, Gilbertson JA, Botcher N, Rowczenio D, Petrie A, et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J 2017;38:1905-8.CrossRefPubMedPubMedCentral
11.
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 2016;133:2404-12.CrossRefPubMed
12.
Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol 2016;68:1323-41.CrossRefPubMed
13.
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2018;379:1007-16.CrossRefPubMed
14.
Gertz MA, Brown ML, Hauser MF, Kyle RA. Utility of technetium Tc 99 m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med 1987;147:1039-44.CrossRefPubMed
15.
Buja LM, Parkey RW, Stokely EM, Bonte FJ, Willerson JT. Pathophysiology of technetium-99 m stannous pyrophosphate and thallium-201 scintigraphy of acute anterior myocardial infarcts in dogs. J Clin Invest 1976;57:1508-22.CrossRefPubMedPubMedCentral
16.
Buja LM, Tofe AJ, Kulkarni PV, Mukherjee A, Parkey RW, Francis MD, et al. Sites and mechanisms of localization of technetium-99 m phosphorus radiopharmaceuticals in acute myocardial infarcts and other tissues. J Clin Invest 1977;60:724-40.CrossRefPubMedPubMedCentral
17.
Dewanjee MK, Kahn PC. Mechanism of localization of 99 mTc-labeled pyrophosphate and tetracycline in infarcted myocardium. J Nucl Med 1976;17:639-46.PubMed
18.
Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol 1979;38:284-93.PubMedPubMedCentral
19.
Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol 2016;25:413-7.CrossRefPubMed
20.
Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99 m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195-201.CrossRefPubMedPubMedCentral
21.
Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, et al. Role of (99 m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc imaging 2011;4:659-70.CrossRefPubMed
22.
Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99 mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84.CrossRefPubMed
23.
Abulizi M, Cottereau AS, Guellich A, Vandeventer S, Galat A, Van Der Gucht A et al. Early-phase myocardial uptake intensity of 99 mTc-HMDP vs 99 mTc-DPD in patients with hereditary transthyretin-related cardiac amyloidosis. J Nucl Cardiol 2016.
24.
Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging 2014;15:1289-98.CrossRefPubMed
25.
Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R et al. Multicenter Study of Planar Technetium 99 m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiol 2016.
26.
Castano A, DeLuca A, Weinberg R, Pozniakoff T, Blaner WS, Pirmohamed A, et al. Serial scanning with technetium pyrophosphate ((99m)Tc-PYP) in advanced ATTR cardiac amyloidosis. J Nucl Cardiol 2016;23:1355-63.CrossRefPubMed
27.
Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38:470-8.CrossRefPubMed
28.
Galat A, Rosso J, Guellich A, Van Der Gucht A, Rappeneau S, Bodez D, et al. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid 2015;22:210-20.CrossRefPubMed
29.
30.
31.
Sperry BW, Gonzalez MH, Brunken R, Cerqueira MD, Hanna M, Jaber WA. Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis. J Nucl Cardiol 2018.
32.
Pilebro B, Suhr OB, Naslund U, Westermark P, Lindqvist P, Sundstrom T. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci 2016;121:17-24.CrossRefPubMedPubMedCentral
33.
Pilebro B, Arvidsson S, Lindqvist P, Sundstrom T, Westermark P, Antoni G, et al. Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR). J Nucl Cardiol 2018;25:240-8.CrossRefPubMed
34.
Cornwell GG 3rd, Murdoch WL, Kyle RA, Westermark P, Pitkanen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 1983;75:618-23.PubMed
35.
36.
Haq M, Pawar S, Berk JL, Miller EJ, Ruberg FL. Can 99m-Tc-Pyrophosphate Aid in Early Detection of Cardiac Involvement in Asymptomatic Variant TTR Amyloidosis? JACC Cardiovasc imaging 2016.
37.
Bennani Smires Y, Victor G, Ribes D, Berry M, Cognet T, Mejean S, et al. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Int J Cardiovasc Imaging 2016;32:1403-13.CrossRefPubMed
38.
Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585-94.CrossRefPubMed
39.
Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017;38:2879-87.CrossRefPubMedPubMedCentral
40.
Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, et al. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol 2018;72:2040-50.CrossRefPubMed
41.
Longhi S, Guidalotti PL, Quarta CC, Gagliardi C, Milandri A, Lorenzini M, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc imaging 2014;7:531-2.CrossRefPubMed
42.
Mohamed-Salem L, Santos-Mateo JJ, Sanchez-Serna J, Hernandez-Vicente A, Reyes-Marle R, Castellon Sanchez MI, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol 2018;270:192-6.CrossRefPubMed
43.
44.
Hutt DF, Fontana M, Burniston M, Quigley AM, Petrie A, Ross JC, et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging 2017;18:1344-50.CrossRefPubMed
45.
Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy; 2014.
46.
Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis; 2014.
47.
Tolerability and Efficacy of a Combination of Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy; 2013.
48.
Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68:319-29.CrossRefPubMed
49.
Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR Jr, Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using (18)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 2014;41:1652-62.CrossRefPubMed
50.
Law WP, Wang WY, Moore PT, Mollee PN, Ng AC. Cardiac amyloid imaging with 18F-florbetaben positron emission tomography: a pilot study. J Nucl Med 2016.
51.
Osborne DR, Acuff SN, Stuckey A, Wall J. A routine PET/CT protocol with simple calculations for assessing cardiac amyloid using 18F-Florbetapir. Front Cardiovasc Med 2015;2:23.CrossRefPubMedPubMedCentral
52.
Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjo L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 2013;54:213-20.CrossRefPubMed
53.
Park MA, Padera RF, Belanger A, Dubey S, Hwang DH, Veeranna V et al. 18F-Florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: Autoradiography Study. Circ Cardiovasc imaging 2015;8:e002954.CrossRefPubMed
54.
Law WP, Wang W, Moore P, Mollee P, Ng A. Cardiac amyloid imaging with (18)F-florbetaben positron emission tomography: a pilot study. Amyloid 2017;24:162.CrossRefPubMed
55.
Dorbala S, Bokhari S, Miller E, Bullock-Palmer R, Soman P, Thompson R. ASNC Practice Points: 99mTechnetium-Pyrophosphate Imaging for Transthyretin Cardiac Amyloidosis 2016.
56.
Longhi S, Lorenzini M, Gagliardi C, Milandri A, Marzocchi A, Marrozzini C, et al. Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis. JACC Cardiovasc imaging 2016;9:325-7.CrossRefPubMed
57.
Hayne DJ, Lim S, Donnelly PS. Metal complexes designed to bind to amyloid-beta for the diagnosis and treatment of Alzheimer’s disease. Chem Soc Rev 2014;43:6701-15.CrossRefPubMed
58.
Metadata
Title
State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis
Authors
Vasvi Singh, MD
Rodney Falk, MD
Marcelo F. Di Carli, MD
Marie Kijewski, PhD
Claudio Rapezzi, MD
Sharmila Dorbala, MD
Publication date
01-02-2019
Publisher
Springer International Publishing
Published in
Journal of Nuclear Cardiology / Issue 1/2019
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-018-01552-4

Other articles of this Issue 1/2019

Journal of Nuclear Cardiology 1/2019 Go to the issue

History Corner

Michael E. Phelps, PhD (born August 24, 1939)

Editorial

Coming-of-age: The ImageGuide™ Registry at three

Images that Teach

Quantification of myocardial blood flow and myocardial flow reserve with SPECT imaging technique

Original Article

Adenosine stress myocardial perfusion imaging in octogenarians: Safety, tolerability, and long-term prognostic implications of hemodynamic response and SPECT-related variables

Review Article

Multimodality imaging: Bird’s eye view from The European Society of Cardiology Congress 2018 Munich, August 25–29, 2018

Original Article

Clinical performance of Rb-82 myocardial perfusion PET and Tc-99m-based SPECT in patients with extreme obesity